Skip to content
Screener

Investing Cash Flow at other companies

Gilead Sciences logo
Gilead SciencesGILD
-$10.35B-389%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$57.05M+130%
LQD
Liquidia CorporationLQDA
-$2.83M-758%
ALN
Alnylam PharmaceuticalsALNY
-$363.46M-157%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$42.74M-2,579%
Arrowhead Research logo
Arrowhead ResearchARWR
-$894.28M-113%

Other financials

Income statement

See full
Revenue$176.2M+37.9%
Operating income-$42.5M-753%
Net income-$67.2M-1,047%
EPS (diluted)-$1.06-783%

Balance sheet

See full
Cash & equivalents$262.7M+39.4%
Total debt$12.9M+29.2%
Total equity-$10.4M-104%
Total assets$1.0B+44.0%

Cash flow

See full
Operating cash flow-$44.3M-468%
CapEx$23.0K-81.7%
Free cash flow-$44.3M-472%

Valuation

See full
Market cap$6.45B+144%
Enterprise value$6.2B+151%
P/S10.4×+4.3×

Profitability

See full
Operating margin-134.9%-151pp
Net margin-139.2%-156pp
FCF margin-37%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001759425-26-000045
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Proceeds from maturities of investments59,73942,497
Purchase of property and equipment(687)(167)
Payments made for additions to intangible assets(35,000)
Net cash used in investing activities(171,560)(22,733)
Financing activities
Proceeds from issuance of convertible notes, net of issuance costs of $17,565672,435
Exchange and repurchase of 2029 convertible notes(474,365)
Proceeds from issuance of common stock and pre-funded warrants in private placement, net of issuance costs of $8,600259,948

Item 1. Financial Statements (Unaudited)

FAQ

What is Mirum Pharmaceuticals, Inc.'s investing cash flow?
Mirum Pharmaceuticals, Inc. (MIRM) reported investing cash flow of -$159.99M in Q2 2026.
How has Mirum Pharmaceuticals, Inc.'s investing cash flow changed year-over-year?
Mirum Pharmaceuticals, Inc.'s investing cash flow decreased by 2324.5% year-over-year, from -$6.6M to -$159.99M.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s investing cash flow?
Over 4 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s investing cash flow has grown at a -15.3% compound annual growth rate (CAGR), from $48.55M to -$24.96M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Mirum Pharmaceuticals, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude